SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis

Cancer Research

Volumn 73, Issue 18, 2013, Pages 5709-5718

  Cronin, Julia C ^a   Watkins Chow, Dawn E ^a   Incao, Art ^a   Hasskamp, Joanne H ^b   Schonewolf, Nicola ^c   Aoude, Lauren G ^d   Hayward, Nicholas K ^d   Bastian, Boris C ^e   Dummer, Reinhard ^c   Loftus, Stacie K ^a   Pavan, William J ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b Maryland Melanoma Center at Medstar Franklin Square Medical Center ^*  (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; METABOTROPIC RECEPTOR 1; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; P27KIP2 PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR SOX10; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENESCENCE; SOMATIC MUTATION; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL AGING; CELL CYCLE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOENZYME TECHNIQUES; MELANOMA; MICE; MICE, TRANSGENIC; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, METABOTROPIC GLUTAMATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOXE TRANSCRIPTION FACTORS;

EID: 84884753364     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4620     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Broekaert SMC, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C, et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010;23:763-70.
3. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011;24:879-97.
4. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-14.
5. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat J-P, et al. A landscape of driver mutations in melanoma. Cell 2012; 150:251-63.
6. Pérez-Lorenzo R, Zheng B. Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci Rep 2012;32:25-33.
7. Narita M, Nuñez S, Heard E, Narita M, Lin AW, Hearn SA, et al. Rbmediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003;113:703-16.
8. Chaoui A, Watanabe Y, Touraine R, Baral V, Goossens M, Pingault V, et al. Identification and functional analysis of SOX10 missense mutations in different subtypes of Waardenburg syndrome. Hum Mutat 2011;32:1436-49.
9. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.
10. Cronin JC, Wunderlich J, Loftus SK, Prickett TD, Wei X, Ridd K, et al. Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res 2009;22:435-44.
11. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002; 109:707-18.
12. Cheli Y, Giuliano S, Guiliano S, Botton T, Rocchi S, Hofman V, et al. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 2011;30: 2307-18.
13. Giuliano S, Cheli Y, Ohanna M, Bonet C, Beuret L, Bille K, et al. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res 2010;70:3813-22.
14. Loercher AE, Tank EMH, Delston RB, Harbour JW. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 2005;168:35-40.
15. Trent JM, Stanbridge EJ, McBride HL, Meese EU, Casey G, Araujo DE, et al. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome. Science 1990;247:568-71.
16. Sharma BK, Manglik V, O'Connell M, Weeraratna A, McCarron EC, Broussard JN, et al. Clonal dominance of CD133 subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma. Int J Oncol 2012;41:1570-6.
17. Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM. Genomescale loss-of-function screening with a lentiviral RNAi library. Nat Methods 2006;3:715-9.
18. Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, et al. A germlineDNApolymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005;65:1213-22.
19. Jang YK, Park JJ, Lee MC, Yoon BH, Yang YS, Yang SE, et al. Retinoic acid-mediated induction of neurons and glial cells from human umbilical cord-derived hematopoietic stem cells. J Neurosci Res 2004;75: 573-84.
20. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003;34:108-12.
21. Britsch S, Goerich DE, Riethmacher D, Peirano RI, Rossner M, Nave KA, et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev 2001;15:66-78.
22. Hodgkinson CA, Moore KJ, Nakayama A, Steingrímsson E, Copeland NG, Jenkins NA, et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helixloop- helix-zipper protein. Cell 1993;74:395-404.
23. Bernex F, De Sepulveda P, Kress C, Elbaz C, Delouis C, Panthier JJ. Spatial and temporal patterns of c-kit-expressing cells in WlacZ/and WlacZ/WlacZ mouse embryos. Development 1996;122:3023-33.
24. Matera I, Watkins-ChowDE, Loftus SK, Hou L, Incao A, Silver DL, et al. A sensitized mutagenesis screen identifies Gli3 as a modifier of Sox10 neurocristopathy. Hum Mol Genet 2008;17:2118-31.
25. Houghton AN, Real FX, Davis LJ, Cordon-Cardo C, Old LJ. Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med 1987;164:812-29.
26. Halaban R. Rb/E2F: a two-edged sword in the melanocytic system. Cancer Metastasis Rev 2005;24:339-56.
27. Li CG, Nyman JE, Braithwaite AW, Eccles MR. PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein. Oncogene 2011;30:4824-34.
28. Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, Rocchi S, et al. The p53/p21Cip1/Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res 2011;24:219-32.
29. Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 2006;20:3426-39.
30. Potterf SB, Furumura M, Dunn KJ, Arnheiter H, Pavan WJ. Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3. Hum Genet 2000;107:1-6.
31. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte- specific transcriptional regulation by MITF. Cancer Cell 2004;6:565-76.
32. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert M-D, Denat L, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005;433:764-9.
33. Liu F, Singh A, Yang Z, Garcia A, Kong Y, Meyskens FL. MiTF links Erk1/2 kinase and p21CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells. Mol Cancer 2010; 9:214.
34. Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, et al. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 2011;43:1119-26.
35. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011;43:442-6.
36. Hornyak TJ, Jiang S,Guzmán EA, Scissors BN, Tuchinda C, He H, et al. Mitf dosage as a primary determinant of melanocyte survival after ultraviolet irradiation. Pigment Cell Melanoma Res 2009;22:307-18.
37. Paraiso KHT, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011;71: 2750-60.
38. Alcala AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 2012;18:33-9.
39. Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol 2008;32:1291-8.
40. Bakos RM, Maier T, Besch R, Mestel DS, Ruzicka T, Sturm RA, et al. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Exp Dermatol 2010;19:e89-94.
41. Agnarsdóttir M, Sooman L, Bolander A, Stromberg S, Rexhepaj E, Bergqvist M, et al. SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Res 2010;20:468-78.
42. Flammiger A, Besch R, Cook AL, Maier T, Sturm RA, Berking C. SOX9 and SOX10 but Not BRN2 are required for nestin expression in human melanoma cells. J Invest Dermatol 2008;129:945-53.
43. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;485:502-6.
44. Hofmann F, Martelli F, Livingston DM, Wang Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev 1996;10:2949-59.
45. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitinproteasome pathway. Cancer Res 1996;56:4620-4.
46. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19:598-609.
47. Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 2012;14:882-90.